Skip to main content

Articles

Page 27 of 61

  1. Reverse cholesterol transport (RCT) is an important cardioprotective mechanism and the decrease in cholesterol efflux can result in the dyslipidemia. Although liraglutide, a glucagon like peptide-1 analogue, h...

    Authors: Ya-Ru Wu, Xiao-Yun Shi, Chun-Yan Ma, Yue Zhang, Rui-Xia Xu and Jian-Jun Li
    Citation: Cardiovascular Diabetology 2019 18:146
    Content type: Original investigation Published on:

  2. Mortality attributable to heart failure remains high. The prevalence of heart failure in patients with diabetes mellitus ranges from 19 to 26%. It is estimated that up to 21.1 million adults in the United Stat...

    Authors: Marcello Ricardo Paulista Markus, Susanne Rospleszcz, Till Ittermann, Sebastian Edgar Baumeister, Sabine Schipf, Ulrike Siewert-Markus, Roberto Lorbeer, Corinna Storz, Violetta Ptushkina, Annette Peters, Christa Meisinger, Fabian Bamberg, Matthias Nauck, Martin Bahls, Henry Völzke, Stephan Burkhard Felix…
    Citation: Cardiovascular Diabetology 2019 18:145
    Content type: Original investigation Published on:

  3. Aim of this study was to evaluate the relationship of plasma PCSK9 with metabolic and inflammatory profile and coronary atherosclerotic burden in patients with suspected CAD enrolled in the EVINCI study.

    Authors: Chiara Caselli, Serena Del Turco, Rosetta Ragusa, Valentina Lorenzoni, Michiel De Graaf, Giuseppina Basta, Arthur Scholte, Raffaele De Caterina and Danilo Neglia
    Citation: Cardiovascular Diabetology 2019 18:144
    Content type: Original investigation Published on:

  4. Excess fat deposition could induce phenotypic changes of perivascular adipose tissue (PVAT remodeling), which may promote the progression of atherosclerosis via modulation of adipocytokine secretion. However, ...

    Authors: Yusaku Mori, Michishige Terasaki, Munenori Hiromura, Tomomi Saito, Hideki Kushima, Masakazu Koshibu, Naoya Osaka, Makoto Ohara, Tomoyasu Fukui, Hirokazu Ohtaki, Hirano Tsutomu and Sho-ichi Yamagishi
    Citation: Cardiovascular Diabetology 2019 18:143
    Content type: Original investigation Published on:

  5. Hyperglycemia in the setting of an acute coronary syndrome (ACS) impacts short term outcomes, but little is known about longer term effects. We therefore designed this study to firstly determine the associatio...

    Authors: Patric Winzap, Allan Davies, Roland Klingenberg, Slayman Obeid, Marco Roffi, François Mach, Lorenz Räber, Stephan Windecker, Christian Templin, Fabian Nietlispach, David Nanchen, Baris Gencer, Olivier Muller, Christian M. Matter, Arnold von Eckardstein and Thomas F. Lüscher
    Citation: Cardiovascular Diabetology 2019 18:142
    Content type: Original investigation Published on:

  6. Long-term treatment with up to 1.8 mg liraglutide improves cardiovascular and all-cause mortality in patients with type 2 diabetes at high risk for cardiovascular disease (CVD) and is currently under investiga...

    Authors: Natia Peradze, Olivia M. Farr, Nikolaos Perakakis, Iolanda Lázaro, Aleix Sala-Vila and Christos S. Mantzoros
    Citation: Cardiovascular Diabetology 2019 18:141
    Content type: Original investigation Published on:

  7. Gestational diabetes mellitus (GDM) is defined as the presence of high blood glucose levels with the onset, or detected for the first time during pregnancy, as a result of increased insulin resistance. GDM may...

    Authors: A. Lorenzo-Almorós, T. Hang, C. Peiró, L. Soriano-Guillén, J. Egido, J. Tuñón and Ó. Lorenzo
    Citation: Cardiovascular Diabetology 2019 18:140
    Content type: Review Published on:

  8. The aim of the present study was to identify a threshold for the cholesterol level at which the risk of cardiovascular disease (CVD) begins to increase in people with type 2 diabetes mellitus (DM).

    Authors: Mee Kyoung Kim, Kyungdo Han, Han Na Joung, Ki-Hyun Baek, Ki-Ho Song and Hyuk-Sang Kwon
    Citation: Cardiovascular Diabetology 2019 18:139
    Content type: Original investigation Published on:

  9. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanism...

    Authors: Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, David W. Boulton, Marcus Thuresson, Hiddo J. L. Heerspink, Stephanie Gustavson, C. David Sjöström, James A. Ruggles, Adrian F. Hernandez, John B. Buse, Robert J. Mentz and Rury R. Holman
    Citation: Cardiovascular Diabetology 2019 18:138
    Content type: Original investigation Published on:

  10. Visceral fat area (VFA) is a good surrogate marker of obesity-related disorders, such as hypertension, dyslipidemia and glucose intolerance. Although estimating the VFA by X-ray computed tomography (CT) is the...

    Authors: Yoko Omura-Ohata, Cheol Son, Hisashi Makino, Ryo Koezuka, Mayu Tochiya, Tamiko Tamanaha, Ichiro Kishimoto and Kiminori Hosoda
    Citation: Cardiovascular Diabetology 2019 18:137
    Content type: Original investigation Published on:

  11. Diabetes mellitus (DM) or pre-diabetes status is closely associated with features of vulnerable coronary lesions in patients with stable coronary heart disease or acute coronary syndrome. However, the associat...

    Authors: Zhaoxue Sheng, Peng Zhou, Chen Liu, Jiannan Li, Runzhen Chen, Jinying Zhou, Li Song, Hanjun Zhao and Hongbing Yan
    Citation: Cardiovascular Diabetology 2019 18:136
    Content type: Original investigation Published on:

  12. Alpha-glucosidase inhibitors (AGIs) have been shown to reduce incident type 2 diabetes but their impact on cardiovascular (CV) disease remains controversial. We sought to identify the overall impact of AGIs wi...

    Authors: Ruth L. Coleman, Charles A. B. Scott, Zhihui Lang, M. Angelyn Bethel, Jaakko Tuomilehto and Rury R. Holman
    Citation: Cardiovascular Diabetology 2019 18:135
    Content type: Original investigation Published on:

  13. The aim of the present study is to examine the effects of free fatty acids (FFAs) on major cardiovascular events (MACEs) in patients with stable coronary artery disease (CAD) and different glucose metabolism s...

    Authors: Jing-Lu Jin, Ye-Xuan Cao, Hui-Hui Liu, Hui-Wen Zhang, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Rui-Xia Xu, Ying Gao, Jing Sun, Qian Dong and Jian-Jun Li
    Citation: Cardiovascular Diabetology 2019 18:134
    Content type: Original investigation Published on:

  14. The pathogenesis and cardiovascular impact of type 2 diabetes (T2D) may be different in South Asians compared with other ethnic groups. The phenotypic characterization of diabetic cardiomyopathy remains debate...

    Authors: Elisabeth H. M. Paiman, Huub J. van Eyk, Maurice B. Bizino, Ilona A. Dekkers, Paul de Heer, Johannes W. A. Smit, Ingrid M. Jazet and Hildo J. Lamb
    Citation: Cardiovascular Diabetology 2019 18:133
    Content type: Original investigation Published on:

  15. Diabetes mellitus (DM) is a major cause of morbidity and mortality following heart transplantation (HT), with 21% and 35% of survivors being affected within 1 and 5 years following HT, respectively. Magnesium ...

    Authors: Yael Peled, Eilon Ram, Jacob Lavee, Alexander Tenenbaum, Enrique Z. Fisman, Dov Freimark, Robert Klempfner, Leonid Sternik and Michael Shechter
    Citation: Cardiovascular Diabetology 2019 18:132
    Content type: Original investigation Published on:

  16. Accumulating evidence has shown that type 2 diabetes (T2D) and coronary artery disease (CAD) may stem from a ‘common soil’. The aim of our study was to examine the association between genetic predisposition to...

    Authors: Qiwen Zheng, Jie Jiang, Yong Huo and Dafang Chen
    Citation: Cardiovascular Diabetology 2019 18:131
    Content type: Original investigation Published on:

  17. Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with d...

    Authors: Julie R. Lundgren, Kristine Færch, Daniel R. Witte, Anna E. Jonsson, Oluf Pedersen, Torben Hansen, Torsten Lauritzen, Jens J. Holst, Dorte Vistisen, Marit E. Jørgensen, Signe S. Torekov and Nanna B. Johansen
    Citation: Cardiovascular Diabetology 2019 18:130
    Content type: Original investigation Published on:

  18. Four large-scale trials in type 2 diabetes have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent the occurrence of serious heart failure events. Additionally, the DAPA-HF trial demonstrated...

    Authors: Milton Packer
    Citation: Cardiovascular Diabetology 2019 18:129
    Content type: Commentary Published on:

  19. Being obese or underweight, and having diabetes are important risk factors for new-onset atrial fibrillation (AF). However, it is unclear whether there is any interaction between body weight and diabetes in re...

    Authors: Yun Gi Kim, Kyung-Do Han, Jong-Il Choi, Ki Yung Boo, Do Young Kim, Suk-Kyu Oh, Kwang-No Lee, Jaemin Shim, Jin Seok Kim and Young-Hoon Kim
    Citation: Cardiovascular Diabetology 2019 18:128
    Content type: Original investigation Published on:

  20. Dyslipidaemia and low-grade inflammation are central in atherogenesis and linked to overweight and physical inactivity. Lifestyle changes are important in secondary prevention of coronary artery disease (CAD)....

    Authors: Lene Rørholm Pedersen, Rasmus Huan Olsen, Christian Anholm, Arne Astrup, Jesper Eugen-Olsen, Mogens Fenger, Lene Simonsen, Rosemary L. Walzem, Steen Bendix Haugaard and Eva Prescott
    Citation: Cardiovascular Diabetology 2019 18:127
    Content type: Original investigation Published on:

  21. Pericoronary adipose tissue inflammation might lead to the development and destabilization of coronary plaques in prediabetic patients. Here, we evaluated inflammation and leptin to adiponectin ratio in perico...

    Authors: Celestino Sardu, Nunzia D’Onofrio, Michele Torella, Michele Portoghese, Francesco Loreni, Simone Mureddu, Giuseppe Signoriello, Lucia Scisciola, Michelangela Barbieri, Maria Rosaria Rizzo, Marilena Galdiero, Marisa De Feo, Maria Luisa Balestrieri, Giuseppe Paolisso and Raffaele Marfella
    Citation: Cardiovascular Diabetology 2019 18:126
    Content type: Original investigation Published on:

  22. Insulin resistance (IR) is considered as a risk factor for atrial fibrillation (AF) even before diabetes develops. The pathophysiology and underlying mechanism are largely unclear.

    Authors: Yi-Hsin Chan, Gwo-Jyh Chang, Ying-Ju Lai, Wei-Jan Chen, Shang-Hung Chang, Li-Man Hung, Chi-Tai Kuo and Yung-Hsin Yeh
    Citation: Cardiovascular Diabetology 2019 18:125
    Content type: Original investigation Published on:

  23. Gene coding mutations found in sodium glucose co-transporters (SGLTs) are known to cause renal glucosuria. SGLT2 inhibitors have recently been shown to be effective hypoglycemic agents as well as possessing ca...

    Authors: Boris Fishman, Gadi Shlomai, Gilad Twig, Estela Derazne, Alexander Tenenbaum, Enrique Z. Fisman, Adi Leiba and Ehud Grossman
    Citation: Cardiovascular Diabetology 2019 18:124
    Content type: Original investigation Published on:

  24. Patients with Diabetes mellitus (DM) are susceptible to coronary artery disease (CAD). However, the impact of DM on plaque progression in the non-stented segments of stent-implanted patients has been rarely re...

    Authors: Rui Shi, Ke Shi, Zhi-gang Yang, Ying-kun Guo, Kai-yue Diao, Yue Gao, Yi Zhang and Shan Huang
    Citation: Cardiovascular Diabetology 2019 18:123
    Content type: Original investigation Published on:

  25. Coronary calcification is associated with high risk for cardiovascular events. However, its impact on plaque vulnerability is incompletely understood. In the present study we defined the intrinsic calcificatio...

    Authors: Sebastian Reith, Andrea Milzi, Enrico Domenico Lemma, Rosalia Dettori, Kathrin Burgmaier, Nikolaus Marx and Mathias Burgmaier
    Citation: Cardiovascular Diabetology 2019 18:122
    Content type: Original investigation Published on:

  26. Both obesity and type 2 diabetes are important risk factors for atrial fibrillation (AF), possibly because they both cause an expansion of epicardial adipose tissue, which is the source of proinflammatory adip...

    Authors: Milton Packer
    Citation: Cardiovascular Diabetology 2019 18:121
    Content type: Hypothesis Published on:

  27. To compare the cardiovascular event risk in type 2 diabetes patients newly receiving dapagliflozin vs. empagliflozin.

    Authors: Shih-Chieh Shao, Kai-Cheng Chang, Ming-Jui Hung, Ning-I Yang, Yuk-Ying Chan, Hui-Yu Chen, Yea-Huei Kao Yang and Edward Chia-Cheng Lai
    Citation: Cardiovascular Diabetology 2019 18:120
    Content type: Original investigation Published on:

  28. Recently, several randomized trials have noted improved outcomes with staged percutaneous coronary intervention (PCI) of nonculprit vessels in patients with ST-segment elevation myocardial infarction (STEMI) a...

    Authors: Kongyong Cui, Shuzheng Lyu, Hong Liu, Xiantao Song, Fei Yuan, Feng Xu, Min Zhang, Wei Wang, Mingduo Zhang, Dongfeng Zhang and Jinfan Tian
    Citation: Cardiovascular Diabetology 2019 18:119
    Content type: Original investigation Published on:

  29. Cardiac allograft vasculopathy (CAV) is a major cause of morbidity and mortality following heart transplantation (HT). Reduced cardiovascular mortality and morbidity have been reported in non-HT patients treat...

    Authors: Eilon Ram, Jacob Lavee, Alexander Tenenbaum, Robert Klempfner, Enrique Z. Fisman, Elad Maor, Tal Ovdat, Sergei Amunts, Leonid Sternik and Yael Peled
    Citation: Cardiovascular Diabetology 2019 18:118
    Content type: Original investigation Published on:

  30. Complication screening is recommended for patients with type 2 diabetes (T2D), but the optimal screening intensity and schedules are unknown. In this study, we evaluated whether intensive versus standard compl...

    Authors: Mario Luca Morieri, Enrico Longato, Marta Mazzucato, Barbara Di Camillo, Arianna Cocchiglia, Lorenzo Gubian, Giovanni Sparacino, Angelo Avogaro, Gian Paolo Fadini and Saula Vigili de Kreutzenberg
    Citation: Cardiovascular Diabetology 2019 18:117
    Content type: Original investigation Published on:

  31. To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

    Authors: Michael A. Nauck, Darren K. McGuire, Karen S. Pieper, Yuliya Lokhnygina, Timo E. Strandberg, Axel Riefflin, Tuncay Delibasi, Eric D. Peterson, Harvey D. White, Russell Scott and Rury R. Holman
    Citation: Cardiovascular Diabetology 2019 18:116
    Content type: Original investigation Published on:

  32. EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular di...

    Authors: Guntram Schernthaner, Avraham Karasik, Agnė Abraitienė, Alexander S. Ametov, Zsolt Gaàl, Janusz Gumprecht, Andrej Janež, Susanne Kaser, Katarina Lalić, Boris N. Mankovsky, Evgeny Moshkovich, Marju Past, Martin Prázný, Gabriela Radulian, Lea Smirčić Duvnjak, Ivan Tkáč…
    Citation: Cardiovascular Diabetology 2019 18:115
    Content type: Commentary Published on:

  33. Cardiac fat is a cardiovascular biomarker but its importance in patients with type 2 diabetes is not clear. The aim was to evaluate the predictive potential of epicardial (EAT), pericardial (PAT) and total car...

    Authors: Regitse H. Christensen, Bernt Johan von Scholten, Christian S. Hansen, Magnus T. Jensen, Tina Vilsbøll, Peter Rossing and Peter G. Jørgensen
    Citation: Cardiovascular Diabetology 2019 18:114
    Content type: Original investigation Published on:

  34. In the light of growing global epidemic of type 2 diabetes mellitus (T2DM), significant efforts are made to discover next-generation biomarkers for early detection of the disease. Multiple mechanisms including...

    Authors: Justyna Pordzik, Daniel Jakubik, Joanna Jarosz-Popek, Zofia Wicik, Ceren Eyileten, Salvatore De Rosa, Ciro Indolfi, Jolanta M. Siller-Matula, Pamela Czajka and Marek Postula
    Citation: Cardiovascular Diabetology 2019 18:113
    Content type: Review Published on:

  35. Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular events. Comparative effectiveness of these new ...

    Authors: Yue Fei, Man-Fung Tsoi and Bernard Man Yung Cheung
    Citation: Cardiovascular Diabetology 2019 18:112
    Content type: Original investigation Published on:

  36. There is no clearly defined temporal relationship between arterial stiffness and diabetes. We aimed to investigate the prospective association between baseline brachial–ankle pulse wave velocity (baPWV) and th...

    Authors: Yuanyuan Zhang, Panpan He, Youbao Li, Yan Zhang, Jianping Li, Min Liang, Guobao Wang, Genfu Tang, Yun Song, Binyan Wang, Chengzhang Liu, Lishun Liu, Yimin Cui, Xiaobin Wang, Yong Huo, Xiping Xu…
    Citation: Cardiovascular Diabetology 2019 18:111
    Content type: Original investigation Published on:

  37. The Y-AIDA study was designed to investigate the renal- and home blood pressure (BP)-modulating effects of add-on dapagliflozin treatment in Japanese individuals with type 2 diabetes mellitus (T2DM) and albumi...

    Authors: Sho Kinguchi, Hiromichi Wakui, Yuzuru Ito, Yoshinobu Kondo, Kengo Azushima, Uru Osada, Tadashi Yamakawa, Tamio Iwamoto, Jun Yutoh, Toshihiro Misumi, Kazutaka Aoki, Gen Yasuda, Taishi Yoshii, Takayuki Yamada, Syuji Ono, Tomoko Shibasaki-Kurita…
    Citation: Cardiovascular Diabetology 2019 18:110
    Content type: Original investigation Published on:

  38. Inflammation and insulin resistance play crucial roles in the development of type 2 diabetes mellitus (T2DM). We aim to examine the temporal relationship between high-sensitivity C-reactive protein (hsCRP) and...

    Authors: Yinkun Yan, Shengxu Li, Yang Liu, Lydia Bazzano, Jiang He, Jie Mi and Wei Chen
    Citation: Cardiovascular Diabetology 2019 18:109
    Content type: Original investigation Published on:

  39. The territory of the right coronary artery (RCA) is smaller than that of the left anterior descending artery. Previous studies have reported conflicting results when considering whether stable RCA-chronic tota...

    Authors: Yunfeng Yan, Mingduo Zhang, Fei Yuan, Hong Liu, Di Wu, Yudong Fan, Xinjing Guo, Feng Xu, Min Zhang, Quanming Zhao and Shuzheng Lyu
    Citation: Cardiovascular Diabetology 2019 18:108
    Content type: Original investigation Published on:

  40. Heart failure with preserved ejection fraction (HFpEF) is a difficult disease with high morbidity and mortality rates and lacks an effective treatment. Here, we report the therapeutic effect of dapagliflozin, ...

    Authors: Nannan Zhang, Bin Feng, Xuexing Ma, Kangyun Sun, Guidong Xu and Yafeng Zhou
    Citation: Cardiovascular Diabetology 2019 18:107
    Content type: Original investigation Published on:

  41. Cardiovascular outcome trials have documented a strong benefit of sodium glucose cotransporter-2 inhibitors (SGLT2i) on the risk of hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D)...

    Authors: Benedetta Maria Bonora, Saula Vigili de Kreutzenberg, Angelo Avogaro and Gian Paolo Fadini
    Citation: Cardiovascular Diabetology 2019 18:106
    Content type: Original investigation Published on:

  42. Although adiponectin is a major adipocytokine that affects the pathogenesis of various cardiovascular diseases, its clinical significance in stroke remains controversial. The purpose of this study was to asses...

    Authors: Zengliang Wang, Bo Li, Yongxin Wang, Aisha Maimaitili, Hu Qin, Geng Dangmurenjiafu and Shuo Wang
    Citation: Cardiovascular Diabetology 2019 18:105
    Content type: Original investigation Published on:

  43. To examine the effect of high-intensity interval training (HIIT) on metabolic syndrome (MetS) and body composition in cardiac rehabilitation (CR) patients with myocardial infarction (MI).

    Authors: Yaoshan Dun, Randal J. Thomas, Joshua R. Smith, Jose R. Medina-Inojosa, Ray W. Squires, Amanda R. Bonikowske, Hsuhang Huang, Suixin Liu and Thomas P. Olson
    Citation: Cardiovascular Diabetology 2019 18:104
    Content type: Original investigation Published on:

  44. We investigated the association regarding severe hypoglycemia episodes with cardiovascular disease risk and all-cause mortality in patients with type 2 diabetes.

    Authors: Jae-Seung Yun, Yong-Moon Park, Kyungdo Han, Seon-Ah Cha, Yu-Bae Ahn and Seung-Hyun Ko
    Citation: Cardiovascular Diabetology 2019 18:103
    Content type: Original investigation Published on:

  45. Myocardial infarction is the main mortality cause in patients with type 2 diabetes (T2DM). Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step of atherogenesis. Asymmet...

    Authors: Gaia Chiara Mannino, Serena Pezzilli, Carolina Averta, Anastasia Fuoco, Rosangela Spiga, Elettra Mancuso, Concetta Di Fatta, Francesco Perticone, Sabrina Prudente, Vincenzo Trischitta, Francesco Andreozzi and Giorgio Sesti
    Citation: Cardiovascular Diabetology 2019 18:102
    Content type: Original investigation Published on:

  46. Following publication of the original article [1], the authors reported an error in Fig. 3. The bars in the upper right panel that represent heart rate in placebo treated patients is not correct.

    Authors: Maurice B. Bizino, Ingrid M. Jazet, Jos J. M. Westenberg, Huub J. van Eyk, Elisabeth H. M. Paiman, Jan W. A. Smit and Hildebrandus J. Lamb
    Citation: Cardiovascular Diabetology 2019 18:101
    Content type: Correction Published on:

    The original article was published in Cardiovascular Diabetology 2019 18:55

  47. Adverse cardiac remodeling after ST-segment elevation myocardial infarction (STEMI) is a major cause for poor cardiovascular outcomes such as heart failure. The predisposing factors and underlying mechanisms r...

    Authors: Chen Die Yang, Ying Shen, Lin Lu, Feng Hua Ding, Zhen Kun Yang, Rui Yan Zhang, Wei Feng Shen, Wei Jin and Xiao Qun Wang
    Citation: Cardiovascular Diabetology 2019 18:100
    Content type: Original investigation Published on:

  48. To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Pr...

    Authors: Aaron Y. Kluger, Kristen M. Tecson, Andy Y. Lee, Edgar V. Lerma, Janani Rangaswami, Norman E. Lepor, Michael E. Cobble and Peter A. McCullough
    Citation: Cardiovascular Diabetology 2019 18:99
    Content type: Review Published on:

  49. Large changes in health behaviors achieved through intensive lifestyle intervention programs improve cardiovascular disease (CVD) risk factors among adults with type 2 diabetes. However, such interventions are...

    Authors: Jean Strelitz, Amy L. Ahern, Gráinne H. Long, Clare E. Boothby, Nicholas J. Wareham and Simon J. Griffin
    Citation: Cardiovascular Diabetology 2019 18:98
    Content type: Original investigation Published on:

  50. Associations between sex hormones and vascular remodeling have been extensively studied, but the results vary widely among different races and sex. We aimed to investigate whether total testosterone (TT), estr...

    Authors: Chiyu Wang, Wen Zhang, Yuying Wang, Heng Wan, Yi Chen, Fangzhen Xia, Kun Zhang, Ningjian Wang and Yingli Lu
    Citation: Cardiovascular Diabetology 2019 18:97
    Content type: Original investigation Published on:
journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

  • 2022 Citation Impact
    9.3 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    2.054 - SNIP (Source Normalized Impact per Paper)
    2.361 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    56 days submission to accept (Median)

    2023 Usage 
    2,523,778 downloads
    3,115 Altmetric mentions 

Cardiovascular Diabetology

ISSN: 1475-2840